SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 8, 2020, Will McGuire submitted his resignation as President and Chief Executive Officer of Second Sight Medical Products, Inc. (the “Company”) to the Company’s Board of Directors (the “Board”) effective March 27, 2020. Mr. McGuire remains a member of the Board. The Board appointed Gregg Williams, Chairman of the Board, as Acting Chief Executive Officer effective upon Mr. McGuire’s departure. John T. Blake, Chief Financial Officer and Pat Ryan, Chief Operating Officer will report to Mr. Williams. The Board is initiating a search process in order to identify and recruit an experienced and qualified successor. On March 12, 2020, the Company issued a press release entitled Second Sight Announces Departure of Will McGuire, President and CEO, and Appointment of Gregg Williams as Acting CEO.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
Exhibit No. Description
SECOND SIGHT MEDICAL PRODUCTS INC Exhibit
EX-99.1 2 eyes-ex991_6.htm EX-99.1 eyes-ex991_6.htm Ex 99.1 FOR IMMEDIATE RELEASE Second Sight Announces Departure of Will McGuire,…
To view the full exhibit click here
About SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES)
Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. The Company’s Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The Argus II System works by converting video images captured by a miniature camera housed in a patient’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina.
